RaySearch Laboratories AB (publ) Year-end Report 2015

“Our success with RayStation® continues and during the year, the order intake for RayStation® doubled to SEK 317 M (159). Overall, revenues rose 39 percent and we are presenting the best full-year results ever, despite continued expansion of our global market organization. We are also seeing a huge interest in RayCare®, for which we have now signed a long-term collaboration agreement with the University of California, San Francisco. RayCare® is an innovative oncology information system and represents a completely new product area for RaySearch. Based on the company’s increased profit, the Board of Directors proposes that dividend payments be resumed,” says Johan Löf, President and CEO of RaySearch.

TWELVE MONTHS (JANUARY-DECEMBER, 2015)

• Net sales SEK 397.6 M (285.2), of which RayStation® SEK 300.4 M (190.2)
• Profit after tax SEK 70.2 M (59.8), and earnings per share SEK 2.05 (1.75)
• Operating profit SEK 95.3 M (79.4)
• Cash flow SEK 3.6 M (16.8)
• Order intake excluding service agreements SEK 385.2 M (229.8), of which RayStation® SEK 316.9 M (158.9)
• Based on the company’s increased profitability, the Board of Directors proposes that dividend payments be resumed with a full-year 2015 dividend of SEK 0.25 per share

FOURTH QUARTER (OCTOBER-DECEMBER, 2015)

• Net sales SEK 132.0 M (107.8), of which RayStation® SEK 109.4 M (84.9)
• Profit after tax SEK 33.3 M (40.7), and earnings per share SEK 0.97 (1.19)
• Operating profit SEK 44.3 M (52.8)
• Cash flow SEK 12.4 M (30.7)
• Cash SEK 59,7 M (56,1) at the end of the period
• Order intake excluding service agreements SEK 117.9 M (85.4), of which RayStation® SEK 102.9 M (70.4)
• At the end of the period, RayStation® order backlog totaled SEK 60.5 M (31.5)

SIGNIFICANT EVENTS DURING THE FOURTH QUARTER

• In November 2015, Anders Liander, CTO, left the company to pursue his own interests
• In November 2015, 1,061,577 Class A shares were converted to Class B shares at the request of a shareholder. The total number of votes in RaySearch thereafter amounted to 126,648,099. The total number of registered shares in RaySearch amounts to 34,282,773, of which 10,262,814 are Class A shares and 24,019,959 are Class B shares

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

• RaySearch has released RayStation® 5 with support for carbon ion treatment planning, which represents the most advanced form of radiation therapy, as well as tools and functionality that bring a new perspective to treatment planning
• RaySearch has signed a long-term collaboration agreement with the University of California, San Francisco (UCSF) regarding the RayCare® oncology information system, which is currently under development at RaySearch
• On January 4, 2016, RaySearch’s Class B share (RAY B) was transferred from the Small Cap to the Mid Cap segment of Nasdaq Stockholm

FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, President and CEO
Tel: +46 8 510 530 00
johan.lof@raysearchlabs.com

The information in this interim report is such that RaySearch is required to disclose publicly in accordance with the Swedish Securities and Clearing Operations Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication on February 18, 2016 at 7:45 a.m.

ABOUT RAYSEARCH
RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institute in Stockholm, and the company is listed in the Mid Cap segment on Nasdaq Stockholm. More information about RaySearch is available at www.raysearchlabs.com.

Tags: